At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Apr 28, 2026 at 19:42 ET
Oruka Therapeutics priced an upsized underwritten public offering of 9.66 million shares at $72.50 per share, raising approximately $700.4 million in gross proceeds. The substantial dilution (~18% of current shares outstanding) is likely to pressure the stock near term, though the capital bolsters its clinical-stage pipeline.
- Offering of 9,660,000 shares at $72.50 per share
- Gross proceeds of ~$700.4 million
- Underwriters have 30-day option for additional 1,449,000 shares
- Expected closing on April 30, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access